Guideline No. 410: Prevention, Screening, Diagnosis, and Pregnancy Management for Fetal Neural Tube Defects

被引:24
|
作者
Wilson, R. Douglas
Van Mieghem, Tim
Langlois, Sylvie
Church, Paige
机构
[1] Calgary, AB
[2] Toronto, ON
[3] Vancouver, BC
关键词
spina bifida; neural tube defects; myelomeningocele; prenatal diagnosis; fetal surgery; neural tube defect prevention; neural tube defect screening; neural tube defect diagnosis; neural tube defect management; OPEN SPINA-BIFIDA; MATERNAL RISK-FACTORS; QUALITY-OF-LIFE; PRENATAL-DIAGNOSIS; FOLIC-ACID; CESAREAN-SECTION; INTRACRANIAL TRANSLUCENCY; FETOSCOPIC SURGERY; 1ST TRIMESTER; YOUNG-PEOPLE;
D O I
10.1016/j.jogc.2020.11.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: This revised guideline is intended to provide an update on the genetic aspects, prevention, screening, diagnosis, and management of fetal neural tube defects. Target population: Women who are pregnant or may become pregnant. Neural tube defect screening should be offered to all pregnant women. Options: For prevention: a folate-rich diet, and folic acid and vitamin B12 supplementation, with dosage depending on risk level. For screening: second-trimester anatomical sonography; first-trimester sonographic screening; maternal serum alpha fetoprotein; prenatal magnetic resonance imaging. For genetic testing: diagnostic amniocentesis with chromosomal microarray and amniotic fluid alpha fetoprotein and acetylcholinesterase; fetal exome sequencing. For pregnancy management: prenatal surgical repair; postnatal surgical repair; pregnancy termination with autopsy. For subsequent pregnancies: prevention and screening options and counselling. Outcomes: The research on and implementation of fetal surgery for prenatally diagnosed myelomeningocele has added a significant treatment option to the previous options (postnatal repair or pregnancy termination), but this new option carries an increased risk of maternal morbidity. Significant improvements in health and quality of life, both for the mother and the infant, have been shown to result from the prevention, screening, diagnosis, and treatment of fetal neural tube defects. Benefits, harms, and costs: The benefits for patient autonomy and decision-making are provided in the guideline. Harms include an unexpected fetal diagnosis and the subsequent management decisions. Harm can also result if the patient declines routine sonographic scans or if counselling and access to care for neural tube defects are delayed. Cost analysis (personal, family, health care) is not within the scope of this clinical practice guideline. Evidence: A directed and focused literature review was conducted using the search terms spina bifida, neural tube defect, myelomeningocele, prenatal diagnosis, fetal surgery, neural tube defect prevention, neural tube defect screening, neural tube defect diagnosis, and neural tube defect management in order to update and revise this guideline. A peer review process was used for content validation and clarity, with appropriate ethical considerations. Validation Methods: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and weak recommendations). Intended Audience: Maternity care professionals who provide any part of pre-conception, antenatal, delivery, and neonatal care. This guideline is also appropriate for patient education.
引用
收藏
页码:124 / +
页数:24
相关论文
共 50 条
  • [31] Efficacy of folic acid prophylaxis for the prevention of neural tube defects
    Watkins, ML
    MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 1998, 4 (04): : 282 - 290
  • [32] Identification of Biomarkers by Proteomics for Prenatal Screening for Neural Tube Defects
    Shen, Guosong
    He, Pingya
    Du, Ying
    Zhang, Su
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 238 (02) : 123 - 129
  • [33] Fetal surgery for neural tube defects
    Niforatos, Nickie
    du Plessis, Adre J.
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2013, 98 (03): : F276 - F278
  • [34] Magnetic resonance imaging in the prenatal diagnosis of neural tube defects
    Zugazaga Cortazar A.
    Martín Martinez C.
    Duran Feliubadalo C.
    Bella Cueto M.R.
    Serra L.
    Insights into Imaging, 2013, 4 (2) : 225 - 237
  • [35] Prenatal diagnosis and elective termination of neural tube defects in Hawaii, 1986-1997
    Forrester, MB
    Merz, RD
    FETAL DIAGNOSIS AND THERAPY, 2000, 15 (03) : 146 - 151
  • [36] Fetal magnetic resonance imaging in the diagnosis of spinal cord neural tube defects: A prospective study
    Gao, Gan
    Tao, Benzhang
    Chen, Yanyan
    Yang, Jiaqi
    Sun, Mengchun
    Wang, Hui
    Hao, Fangbin
    Liu, Simeng
    Wang, Minjie
    Shang, Aijia
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [37] Neural tube defects: a review of global prevalence, causes, and primary prevention
    Vijaya Kancherla
    Child's Nervous System, 2023, 39 : 1703 - 1710
  • [38] Neural tube defects: a review of global prevalence, causes, and primary prevention
    Kancherla, Vijaya
    CHILDS NERVOUS SYSTEM, 2023, 39 (07) : 1703 - 1710
  • [39] PUBLIC HEALTH PERSPECTIVES OF THE PREVENTION OF NEURAL TUBE DEFECTS WITH FOLIC ACID
    Farkas-Lainscak, Jerneja
    Novak-Antolic, Ziva
    Hlastan-Ribic, Cirila
    Zaletel-Kragelj, Lijana
    ZDRAVSTVENO VARSTVO, 2009, 48 (02): : 68 - 77
  • [40] PREVENTION OF NEURAL-TUBE DEFECTS WITH FOLIC-ACID SUPPLEMENTATION IN EARLY-PREGNANCY
    KOLETZKO, B
    VONKRIES, R
    GYNAKOLOGISCH-GEBURTSHILFLICHE RUNDSCHAU, 1995, 35 (01): : 2 - 5